Chiglitazar Sodium Tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Chemical medicine
- Therapeutic area
- Endocrinology & metabolism
- Indications recorded in the public source
- To improve glycemic control in adults with type 2 diabetes: (1) as monotherapy alongside diet and exercise; (2) in combination with metformin hydrochloride alongside diet and exercise when metformin hydrochloride alone does not provide adequate glycemic control.
- Indication source and scope
- Source date(s): 2024-12-03, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- No additional restriction is specified for this list entry; the list's general rules and approved indications still apply.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/c/2022-06-01/827272.shtml
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.chipscreen.com/media/upload/%E8%A5%BF%E6%A0%BC%E5%88%97%E4%BB%96%E9%92%A0%E7%89%87%E8%AF%B4%E6%98%8E%E4%B9%A6%E3%80%9020241203%E3%80%91%E7%AC%AC%E5%85%AD%E7%89%88.pdf
Open the interactive record, public price references and discussions